3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
5
Phase 1/2
1
Status
Unknown
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Head & Neck
1
Conditions
Carcinoma, Hepatocellular
5
Stomach Neoplasms
4
Advanced Gastric Cancer
3
Neoplasms
2
Lung Neoplasms
2
Carcinoma, Non-Small-Cell Lung
2
Triple Negative Breast Neoplasms
1
Thoracic Neoplasms
1
Small Cell Lung Carcinoma
1
Respiratory Tract Diseases
1
Recurrence
1
Pyloric Stenosis, Hypertrophic
1
Pancreatic Neoplasms
1
Osteosarcoma
1
Neuroblastoma
1
Lymphoma, T-Cell, Peripheral
1
Lymphoma, Large B-Cell, Diffuse
1
Lung Diseases
1
Locally Advanced or Metastatic Gastric Adenocarcinoma
1
Liver Neoplasms
1
Hepatic Metastasis of Colorectal Cancer
1
Head and Neck Neoplasms
1
Glioma
1
Colorectal Neoplasms
1
Colorectal Cancer Recurrent
1
Biliary Tract Neoplasms
1
Advanced Triple Negative Breast Cancer
1
Advanced Solid Tumors
1
Interventions
pembrolizumab
24
Radiotherapy
21
Cisplatin
21
Cetuximab
13
Carboplatin
11
Paclitaxel
8
Nivolumab
8
durvalumab
7
Radiotherapy, Intensity-Modulated
6
Docetaxel
6
Fluorouracil
5
Cyclophosphamide
5
zalutumumab
4
Everolimus
4
Amifostine
4
spartalizumab
3
fludarabine
3
epacadostat
3
cemiplimab
3
Ipilimumab
3
Immune Checkpoint Inhibitors
3
Gefitinib
3
Filgrastim
3
Erlotinib Hydrochloride
3
Celecoxib
3
Capecitabine
3
selpercatinib
2
palbociclib
2
fludarabine phosphate
2
bintrafusp alfa protein, human
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1/2
×
Head and Neck Neoplasms
×
apatinib
×
Clear all
NCT03654612
2018-10-18
Y-HR2017-025
China International Medical Foundation
Phase 1/2
Unknown
30 enrolled